<DOC>
	<DOCNO>NCT01865695</DOCNO>
	<brief_summary>Faecal elastase enzyme test use identify presence pancreatic exocrine insufficiency . This condition manifest symptom diarrhea , weight loss , cause potential impairment individual 's quality life . Creon , pancreatic enzyme supplement , market Abbott Laboratories , Inc. currently standard treatment condition . However , limited work evaluate merit medication condition . This study aim evaluate benefit Creon may coeliac patient low faecal pancreatic elastase randomise patient low faecal pancreatic elastase ( &lt; 200 ug/g ) either treatment Creon placebo . Outcome measure aim ass determine benefit Creon include evaluation stool frequency , abdominal pain , body mass index ( BMI ) quality life .</brief_summary>
	<brief_title>Creon Use Coeliac Patients With Low Faecal Pancreatic Elastase</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Celiac Disease</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>patient coeliac disease chronic diarrhoea ( &gt; 3 loose/ liquid motion day 4 week ) Patients low faecal elastase ( &lt; 200 ug/g ) , Patients age 16 year Patient able give write consent participate Patient currently Creon Patients normal faecal elastase ( &gt; 201ug/g ) , Patients age 16 Patients allergic pork pig product ( advice drug manufacturer ) Patients pregnant breastfeed Patients take alternative medication could affect bowel frequency Where alternative diagnosis chronic diarrhoea establish , patient exclude trial Patients unable speak understand English</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>pancreatic exocrine insufficiency</keyword>
	<keyword>faecal elastase</keyword>
	<keyword>diarrhoea</keyword>
	<keyword>coeliac</keyword>
	<keyword>creon</keyword>
	<keyword>gastrointestinal</keyword>
</DOC>